Found 463 results in Expert Content

This eBook published by Pharmaceutical Technology provides an overview of the regulatory landscape related to elemental impurities testing, discusses the challenges of implementing ICH Q3D guidelines ...

You will learn about a pharmaceutical company who was interested in scaling-up a multi-particulate, modified-release product to a commercial scale using fluid bed bottom-spray (Wurster) coating.

Summary: Given the accelerated timelines associated with expedited programs, lipid-based drug formulations, encapsulated in softgel capsules, provide an attractive option for addressing the challenges...

From the top industry partner for development, launch and supply of new treatments, Catalent offers integrated solutions for pulmonary and nasal delivery with significant capacity in North America. Our in-house capabilities span clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and multi-dose nasal sprays

Lipid based drug delivery systems (LBDDS) are the most studied and understood bioavailability enhancing solutions

Summary: It is vital that drug products reach patients uncontaminated and unadulterated by their packaging. Extractables and leachables (E&L) are especially of concern for liquid injectable...

To be successful, new treatments require real-world outcomes for you, your stakeholders, and most importantly the patients.

The pharmaceutical industry has experienced a trend in the number of accelerated approval designations for drugs (e.g. orphan drugs, breakthrough therapies, accelerated approvals, and FDA priority reviews) being developed.

Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes.

Pharmaceutical and biotechnology companies value streamlined services from early-phase development to clinical supply services to commercialization.